Age-stratified performance of the cervista HPV 16/18 genotyping test in women with ASC-US cytology

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 6, 2011, Pages 1185-1189

  Einstein, Mark H ^a   Garcia, Francisco A R ^b   Mitchell, Amy L ^b   Day, Stephen P ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c HOLOGIC INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; COLPOSCOPY; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; DNA SEQUENCE; FEMALE; GENOTYPE; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; COHORT STUDIES; COLPOSCOPY; CYTODIAGNOSIS; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; PROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 79958034664     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0116     Document Type: Article

References (20)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9. (Pubitemid 29406813)
2. Trottier H, Mahmud SM, Lindsay L, Jenkins D, Quint W, Wieting SL, et al. Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women. Cancer Epidemiol Biomarkers Prev 2009;18:854-62.
3. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-32. (Pubitemid 46986496)
4. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007;197:346-55.
5. Sherman ME, Schiffman M, Cox JT. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst 2002;94:102-7. (Pubitemid 34121289)
6. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-9. (Pubitemid 32219816)
7. ASCCP. HPV Genotyping Clinical Update. 2009. Available from: http://www.asccp.org/pdfs/consensus/clinical-update-20090408.pdf.
8. Einstein MH, Martens MG, Garcia FA, Ferris DG, Mitchell AL, Day SP, et al. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecol Oncol 2010;118:116-22.
9. Bartholomew DA, Luff RD, Quigley NB, Curtis M, Olson MC. Analytical performance of Cervista® HPV 16/18 genotyping test for cervical cancer screening. J Clin Virol 2011;51:38-43
10. Third Wave Technologies Inc. Genfind DNA Extraction Kit. Madison, WI: Third Wave Technologies Inc; 2009.
11. Hall JG, Eis PS, Law SM, Reynaldo LP, Prudent JR, Marshall DJ, et al. Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction. Proc Natl Acad Sci U S A 2000;97:8272-7. (Pubitemid 30639662)
12. Day SP, Hudson A, Mast A, Sander T, Curtis M, Olson S, et al. Analytical performance of the investigational use only CervistaTM HPV HR test as determined by a multi-center study. J Clin Virol 2009;45:S63-72.
13. Castle PE, Solomon D, Schiffman M, Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005;97:1066-71. (Pubitemid 41417923)
14. Wheeler CM, Hunt WC, Schiffman M, Castle PE. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis 2006;194:1291-9. (Pubitemid 44630975)
15. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-9. (Pubitemid 41417924)
16. Stoler MH, Wright TC, Sharma A, Apple R, Gutekunst K, Wright TLThe ATHENA HPV Study Groupl. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 2011;135:468-75.
17. ASCCP. American Society for Colposcopy and Cervical Pathology. 2009. Available from: http://www.asccp.org/.
18. Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006;98:303-15. (Pubitemid 43338210)
19. Meijer CJ, Snijders PJ, Castle PE. Clinical utility of HPV genotyping. Gynecol Oncol 2006;103:12-7. (Pubitemid 44374721)
20. NCI. National Cancer Institute. 2009. Available from: http://www.cancer.gov/.